Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.42 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7876414 | 0.99 | KMT2A (0.57) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL20665020 | 0.90 | KMT2A (0.56) | KMT2AEPHX2CASP3OPRD1CXCR2 | |
| SCHEMBL13319574 | 0.89 | KMT2A (0.59) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL29470973 | 0.88 | KMT2A (0.57) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL12391727 | 0.88 | KMT2A (0.57) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL469368 | 0.88 | KMT2A (0.54) | KMT2AEPHX2CASP3 | |
| SCHEMBL30095461 | 0.88 | KMT2A (0.54) | KMT2AEPHX2CASP3 | |
| SCHEMBL20665019 | 0.88 | KMT2A (0.54) | KMT2AEPHX2CASP3CXCR2 | |
| Hydrochloric Acid SCHEMBL455447 | 0.87 | KMT2A (0.53) | KMT2AEPHX2CASP3OPRD1 | |
| SCHEMBL610115 | 0.87 | KMT2A (0.71) | KMT2AEPHX2CASP3FABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230235328-A1 | NOVEL MORPHOLINO OLIGONUCLEOTIDE DERIVATIVES | Nexoligo Co., Ltd. (KR) | 2023-07-27 | — | — | US | disclosed |
| US-20210171437-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | VERA THERAPEUTICS INC (US) | 2021-06-10 | — | — | US | disclosed |
| US-20190055190-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | NEUBASE THERAPEUTICS, INC. | 2019-02-21 | — | — | US | disclosed |
| WO-2019018422-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TRUCODE GENE REPAIR, INC. (US) | 2019-01-24 | — | — | WO | disclosed |
| EP-2268607-B9 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2015-05-13 | — | — | EP | disclosed |
| EP-2268607-B9 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2015-05-13 | — | — | EP | disclosed |
| EP-2268607-B1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2015-02-18 | — | — | EP | disclosed |
| EP-2268607-B1 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2015-02-18 | — | — | EP | disclosed |
| US-8895734-B2 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid | OLIPASS CORPORATION (KR) | 2014-11-25 | — | — | US | disclosed |
| US-8884008-B2 | Peptide nucleic acid derivatives with good cell penetration and strong affinity for nucleic acid | OLIPASS CORPORATION (KR) | 2014-11-11 | — | — | US | disclosed |
| WO-2009113828-A9 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009113828-A9 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2009-11-05 | — | — | WO | disclosed |
| EP-0840736-B1 | IMPROVED SYNTHONS FOR THE SYNTHESIS AND DEPROTECTION OF PEPTIDE NUCLEIC ACIDS UNDER MILD CONDITIONS | PERSEPTIVE BIOSYSTEMS INC (US) | 2009-10-07 | — | — | EP | disclosed |
| WO-2009113828-A2 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009113828-A2 | PEPTIDE NUCLEIC ACID DERIVATIVES WITH GOOD CELL PENETRATION AND STRONG AFFINITY FOR NUCLEIC ACID | CTI BIO (KR) | 2009-09-17 | — | — | WO | disclosed |
| EP-1873156-A1 | Process for the preparation of 6-[[(alkoxy)carbonyl]amino]-9H-Purine-9-acetic acid and 4-[(alkoxycarbonyl)amino]-2-oxo-1(2H)-Pyrimidineacetic acid derivatives as synthons for the synthesis of peptide nucleic acids | PerSeptive Biosystems, Inc. (US) | 2008-01-02 | — | — | EP | disclosed |
| US-6172226-B1 | Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions | PERSEPTIVE BIOSYSTEMS, INC. | 2001-01-09 | — | — | US | disclosed |
| US-6133444-A | PURINE PEPTIDE NUCLEIC ACIDS SYNTHONS | PERSEPTIVE BIOSYSTEMS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0840736-A1 | IMPROVED SYNTHONS FOR THE SYNTHESIS AND DEPROTECTION OF PEPTIDE NUCLEIC ACIDS UNDER MILD CONDITIONS | PerSeptive Biosystems, Inc. (US) | 1998-05-13 | — | — | EP | disclosed |
| WO-1996040685-A1 | IMPROVED SYNTHONS FOR THE SYNTHESIS AND DEPROTECTION OF PEPTIDE NUCLEIC ACIDS UNDER MILD CONDITIONS | PERSEPTIVE BIOSYSTEMS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230235328-A1 | NOVEL MORPHOLINO OLIGONUCLEOTIDE DERIVATIVES | RNGTT, MPO, RNMT | KMT2A 2236/4885EPHX2 3080/4885CASP3 1470/4885 |
| US-20190055190-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TARBP1, TIA1, SSB | KMT2A 2365/4885EPHX2 593/4885CASP3 1513/4885 |
| US-20210171437-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TARBP1, TIA1, SSB | KMT2A 2365/4885EPHX2 593/4885CASP3 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.